BioSpace News Archive

Pandion Therapeutics, Inc., a biotechnology company developing modular protein therapeutics for autoimmune disease, today announced that Don Frail, PhD will be joining its board of directors as an independent director.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), the leading developer of spider silk based fibers, announced that it is providing an update on Prodigy Textiles’, the Company’s Vietnamese subsidiary, production operations.

Otonomy, Inc. (Nasdaq: OTIC), today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic Technologies Corporation (Nasdaq: AGTC) focused initially on treating GJB2 deficiency for congenital hearing loss, and preclinical results demonstrating the therapeutic potential of a class of compounds being evaluated for otoprotection against cisplatin-induced hearing loss (CIHL).

Zelira Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF) is pleased to announce a collaboration with the Parkinson’s Foundation, one of the United States of America’s leading communities for people living with Parkinson’s disease (PD), to gather insights from people with PD about their understanding of and use of medical cannabis and hemp-derived therapies.

Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced it has received Conformité Européenne (CE) Mark approval to market its Wireless Lumee® Oxygen Platform for continuous, real-time monitoring of tissue oxygen in patients with potential acute and/or chronic changes in tissue oxygen levels who may benefit from monitoring.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that following a Priority Review, Health Canada has approved INVOKANA® (canagliflozin) as an adjunct to diet, exercise, and standard-of-care therapy, to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, and cardiovascular (CV) death in adult patients with type 2 diabetes mellitus and diabetic nephropathy

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received notification of validation of European patent number EP 3356554 for its methods for subtyping diffuse large B-cell lymphoma (DLBCL), effective October 2019.

Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into agreements with BioLexis Pte. Ltd. (“BioLexis”), its largest stockholder, and MTTR, LLC (“MTTR”), its development partner for ONS-5010

Rebecca Cofinas Fox, a health care entrepreneur, executive and advisor, has been named president and chief executive officer of Northwest Kidney Centers.

Hospital for Special Surgery, the world leader in musculoskeletal health, expanded its geographic footprint when it opened the doors of a new 60,000-square-foot facility in West Palm Beach, Florida.